Rare SARS-CoV-2 Antibody Development in Cancer Patients
2020
SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now,
it has been assumed that patients who were infected with SARS-CoV-2 develop antibodies as it is the case with other
coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the antibody development of 77
oncology patients 26 days after positive RT-qPCR testing for SARS-CoV2. RT-qPCR and anti-SARS-CoV2-antibody
methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS-
CoV-2 immunoassay) were used, respectively, according to the manufacturers’ specifications.
Surprisingly, antibody development was detected in only 6 of 77 individuals with a confirmed history of COVID-19.
Despite of multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent
tests. These results undermine the previous hypothesis that SARS-CoV2 infections are regularly associated with
antibody development and cast doubt on the provided immunity to COVID-19. Understanding the adaptive and
humoral response to SARS-CoV2 will play a key-roll in vaccine development and gaining further knowledge on the
pathogenesis.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI